YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Amyotrophic Lateral Sclerosis Therapeutics Market size & share revenue was valued at…
AB Science PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN MEDICINES AGENCY IS EXPECTED DUR…
AB Science PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2036 IN THE TREATMENT OF MASTOCYTOSIS THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY PROTECTION STRATEGY BAS…
AB Science PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN SICKLE CELL DISEASE ON THURSDAY NOVEMBER 30, 2023, FROM 3PM TO 4PM CET Paris, 28 november, 2023, 7.15pm CET AB Science SA (Euronext – FR00…
AB Science PRESS RELEASE THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)". THIS PRO…
AB Science PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION FOR THE FIRST HALF OF 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development strategy based on two platforms: the late-stage masitinib platform and the new microtub…
AB Science PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE EUROPEAN MEDICINES AGENCY'S TIMETABLE FOR EXAMINATIONOF THE MARKETING AUTHORIZATION APPLICATION OF MASITINIBINAMYOTROPHIC LATERAL SCLEROSIS BASED ON THE UPDATED TIMETABLE, A DEC…
AB Science PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERINGMASITINIB IN THE TREATMENT OF METASTATIC CASTRATE REFRACTORY PROSTATE CANCER (mCRPC), STRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION U…
AB Science PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)WITH PROTECTION UNTIL 2037 CANADIAN PATENT COMPLETES INTELLECTUAL PROPERTY COVERAGE FOR ALS AC…
AB Science PRESS RELEASE AB SCIENCE SUMMARIZES KEY MESSAGES FROM ITS PARTICIPATIONTOA PANEL DISCUSSIONAT THE 2023 ALS DRUG DEVELOPMENT SUMMIT(BOSTON, USA) Paris, 17May, 2023, 8:00pmCET AB Science SA (Euronext – FR0010557264 – AB) today sum…
AB Science PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMEDITSREVIEW OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS, FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE LETTER Paris, 09 May, 2023, 6pm C…
AB Science PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2022 AND THE KEY EVENTS OF THE PERIOD Financial information and other corporate information Consolidated operating loss of €15.9 million as of 31 Dec…
AB Science PRESS RELEASE AB SCIENCE SUMMARIZES THE PRESENTATION ON MASITTINIB IN AMYOTROPHIC LATERAL SCLEROSIS MADE AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING, INCLUDING LONG-TERM SURVIVAL ANALYSIS AND NEW ANALYSIS OF PATIENT…
AB Science PRESS RELEASE SUCCESS OF THE CAPITAL INCREASE BY PRIVATE PLACEMENT FOR AN AMOUNT OF 15 MILLION EUROS Paris, April 24, 2023, 8am CET AB Science S.A. (the “Company” or “AB Science”, NYSE Euronext – FR0010557264 – AB), announces to…
AB Science PRESS RELEASE FOCUS OF THE DEVELOPMENT STRATEGY ON AMYOTROPHIC LATERAL SCLEROSIS WITH THE MASITINIB PLATFORM AND ON THE SECOND MICROTUBULE PLATFORM AND SEARCH FOR PARTNERSHIPS FOR NON-RARE DISEASE INDICATIONS OF MASITINIB LAUNCH…
AB Science PRESS RELEASE AB SCIENCE ANNOUNCES MASITINIB PATENTGRANTED IN JAPAN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, STRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION UNTIL 2037 TO DATE, THIS PATENT HAS BEEN GRANTED…
AB Science PRESS RELEASE RESULTS OF MASITINIB IN ALS SELECTED FOR A SCIENTIFIC PLATFORM PRESENTATION AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING, INCLUDING LONG-TERM SURVIVAL ANALYSIS AND NEW ANALYSIS OF PATIENT POPULATION WIT…
AB Science PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS SUBMITTED ITS RESPONSE TO THE DAY 120 QUESTIONS IN THE EMA REGULATORY REVIEW OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AND CLARIFIES THE NEW TIMELINE FOR RESPONDING TO HEALTH CA…
AB Science PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON ITS MICROTUBULE DESTABILIZER AGENTS (MDA)PLATFORM ON THURSDAY MARCH 16, 2023, FROM 6PM TO 7PM CET Paris, 15 March, 2023, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) w…
AB Science PRESS RELEASE AB SCIENCE REPORTS A FIRST COMPLETE BONE MARROW RESPONSE IN A RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENT FROM THE VERY LOWDOSE ARM OF ITS AB8939 PHASE I/II CLINICAL TRIAL (AB18001) AB SCIENCE WILL HOS…
AB Science PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN ALZHEIMER'S DISEASE IN THE JOURNAL ALZHEIMER'S RESEARCH & THERAPY Paris, 28 February, 2023,8amCET AB Science SA (Euronext - FR0010557264 - AB) today an…
AB Science PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE SECOND TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK Paris, January 31, 2023, 6pm CET AB Science SA (Euronext - FR0010557264 - A…
AB Science PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS Paris, December 29 2022…
AB Science PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27, 2022, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that masi…
AB Science PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE FIRST TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK Paris, December 22, 2022, 6pm CET AB Science SA (Euronext - FR0010557264 - A…
AB Science PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF DEFICIENCY (NOD) FROM HEALTH CANADA FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AB SCIENCE HAS 90 CALENDAR DAYS TO RESPOND TO THE NOD Paris, December 13, 2022…
AB Science PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, November 21, 2022, 6pm CET AB…
AB Science PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONSTOINITIATECONFIRMATORY PHASE 3 CLINICAL STUDY WITHMASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th2022, 6pm CET AB Science SA (Euronext - FR0010…
AB Science PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION FOR THE FIRST HALF OF 2022 AND THE KEY EVENTS OF THE PERIOD Clinical development Authorization by Health Canada in February 2022 to file a New Drug Submission for masit…
AB Science PRESS RELEASE POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING BOARD TO CONTINUE THE PHASE 2 STUDY EVALUATING ANTIVIRAL ACTIVITY OF MASITINIB IN COVID-19 Paris, 14 September 2022,6.15pm CET AB Science SA (Euronext - FR0…
AB Science PRESS RELEASE AB SCIENCE ANNOUNCES FILING OF MARKETING AUTHORIZATION APPLICATION FORALSITEKIN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND ITS VALIDATION BY THE EUROPEAN MEDICINES AGENCY (EMA) Paris, 24August 2022,7p…
AB Science PRESS RELEASE AB SCIENCE ANNOUNCES PUBLICATION IN THE JOURNAL OF ASTHMA AND ALLERGYOF POSITIVE MASITINIB PHASE 3 CLINICAL TRIAL RESULTS IN PATIENTS WITH ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA Paris, 7June, 2022,5.45pm CET A…
AB Science PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS STARTEDTHE REVIEW OF NEW DRUG SUBMISSION FOR MASITINIB INTHE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS), FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE LETTER Paris,…
AB Science PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2021 AND THE KEY EVENTS OF THE PERIOD Clinical development Authorization by Health Canada to file a New Drug Submission for masitinib in the treatmen…
AB Science PRESS RELEASE POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING BOARD TO CONTINUE THE PHASE 2 STUDY EVALUATING MASITINIB IN COMBINATION WITH ISOQUERCETIN IN COVID-19 Paris, 28April 2022,8am CET AB Science SA (Euronext -…
AB Science PRESS RELEASE COMMUNICATION FROM AB SCIENCE FOLLOWING THE DECISION OF THE ENFORCEMENT COMMITTEE OF THE FRENCH MARKET REGULATOR (AMF) Paris, 29 March 2022, 7.30pm CET AB Science SA (Euronext - FR0010557264 - AB) acknowledges the…